Charles River Laboratories International (NYSE: CRL ) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Charles River Laboratories International's revenues will expand 0.4% and EPS will expand 8.8%.
The average estimate for revenue is $278.8 million. On the bottom line, the average EPS estimate is $0.62.
Last quarter, Charles River Laboratories International logged revenue of $284.7 million. GAAP reported sales were 1.2% lower than the prior-year quarter's $288.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.75. GAAP EPS of $0.63 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.4%, 50 basis points worse than the prior-year quarter. Operating margin was 17.3%, 120 basis points worse than the prior-year quarter. Net margin was 10.7%, 50 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.14 billion. The average EPS estimate is $2.72.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $39.35.
- Add Charles River Laboratories International to My Watchlist.